Visual outcomes after treatment in pediatric patients with Coats' disease

Can J Ophthalmol. 2019 Dec;54(6):647-652. doi: 10.1016/j.jcjo.2019.02.004. Epub 2019 Apr 9.

Abstract

Objective: To report visual outcomes for children with Coats' disease after treatment.

Design: Retrospective case series.

Participants: Pediatric patients with Coats' disease treated between 2000 and 2018 at a tertiary care pediatric hospital.

Methods: Review of medical records. The primary outcome was visual acuity at final follow-up. Anatomical outcomes, retreatment, and risk factors for a poor outcome were also assessed.

Results: There were 30 patients with Coats' disease. All cases were unilateral, and 28 (93%) were male. At presentation, 14 (47%) had stage 2 disease (retinal exudates) and 16 (53%) had stage 3 disease (subtotal or total exudative retinal detachment). All patients underwent laser photocoagulation and (or) cryopexy as primary treatment, combined with antivascular endothelial growth factor injection in 7 patients, posterior sclerotomy in 5 patients, and pars plana vitrectomy in 1 patient. Retreatment was required in 16 (53%) patients. After a median follow-up of 3.8 years, visual acuity was 20/50 or better in 6 patients (20%), 20/60 to 20/150 in 3 (10%), 20/200 to counting fingers in 8 (23%), and hand motion or worse in 14 (47%). Greater severity of disease at presentation was significantly associated with a poor visual outcome (p = 0.0001). In terms of complications, 7 (23%) eyes developed cataracts and 2 (7%) progressed to phthisis bulbi, but no patients required enucleation.

Conclusions: The visual prognosis for children with Coats' disease remains poor, particularly in patients with more severe disease at presentation. The risk of severe complications and enucleation is low after treatment.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Bevacizumab / therapeutic use
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cryotherapy*
  • Female
  • Follow-Up Studies
  • Hospitals, Pediatric
  • Humans
  • Infant
  • Intravitreal Injections
  • Laser Coagulation*
  • Male
  • Ranibizumab / therapeutic use
  • Retinal Telangiectasis / drug therapy
  • Retinal Telangiectasis / physiopathology*
  • Retinal Telangiectasis / surgery
  • Retinal Telangiectasis / therapy*
  • Retrospective Studies
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology*

Substances

  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Ranibizumab